Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$0.32 - $0.62 $3,944 - $7,641
12,325 Added 2.38%
529,362 $328,000
Q3 2023

Nov 14, 2023

SELL
$0.46 - $0.65 $20,164 - $28,492
-43,835 Reduced 7.82%
517,037 $248,000
Q2 2023

Aug 14, 2023

SELL
$0.57 - $1.08 $1.12 Million - $2.12 Million
-1,962,795 Reduced 77.78%
560,872 $336,000
Q1 2023

May 15, 2023

BUY
$0.66 - $1.29 $95,290 - $186,250
144,380 Added 6.07%
2,523,667 $1.89 Million
Q4 2022

Feb 14, 2023

BUY
$1.1 - $2.45 $25,944 - $57,785
23,586 Added 1.0%
2,379,287 $2.95 Million
Q3 2022

Nov 15, 2022

BUY
$1.96 - $3.32 $219,945 - $372,560
112,217 Added 5.0%
2,355,701 $4.85 Million
Q2 2022

Aug 15, 2022

BUY
$2.27 - $4.86 $296,398 - $634,579
130,572 Added 6.18%
2,243,484 $6.21 Million
Q1 2022

May 16, 2022

BUY
$3.69 - $5.65 $250,038 - $382,849
67,761 Added 3.31%
2,112,912 $9.23 Million
Q4 2021

Feb 14, 2022

BUY
$5.37 - $7.07 $122,269 - $160,976
22,769 Added 1.13%
2,045,151 $11.3 Million
Q3 2021

Nov 15, 2021

BUY
$5.54 - $7.51 $283,105 - $383,776
51,102 Added 2.59%
2,022,382 $12.5 Million
Q2 2021

Aug 16, 2021

SELL
$7.78 - $11.4 $236,823 - $347,016
-30,440 Reduced 1.52%
1,971,280 $16.8 Million
Q1 2021

May 17, 2021

BUY
$5.12 - $8.48 $2.06 Million - $3.41 Million
401,936 Added 25.12%
2,001,720 $15.8 Million
Q4 2020

Feb 16, 2021

BUY
$3.16 - $7.03 $32,200 - $71,635
10,190 Added 0.64%
1,599,784 $9.31 Million
Q3 2020

Nov 10, 2020

BUY
$3.26 - $4.73 $312,630 - $453,602
95,899 Added 6.42%
1,589,594 $5.39 Million
Q2 2020

Aug 14, 2020

BUY
$1.58 - $4.63 $478,740 - $1.4 Million
303,000 Added 25.45%
1,493,695 $6.89 Million
Q1 2020

May 11, 2020

BUY
$1.44 - $3.02 $1.71 Million - $3.6 Million
1,190,695 New
1,190,695 $1.88 Million

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $520M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.